Anti-igf1r antibodies and uses thereof

Anti-IGF1R antibodies with designed CDRs offer enhanced therapeutic potential for cancer and thyroid eye diseases by addressing the limitations of current treatments, providing targeted and effective solutions.

HK40134727APending Publication Date: 2026-07-10NANJING CHIA TAI TIANQING PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
NANJING CHIA TAI TIANQING PHARMA
Filing Date
2026-04-27
Publication Date
2026-07-10

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Anti-IGF1R (Insulin-like Growth Factor 1 Receptor) antibodies, antigen binding fragments and uses thereof are provided.
Need to check novelty before this filing date? Find Prior Art